Received Apr 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 2 | — | — |
a single person with severe asthma experienced worsening symptoms; The initial case was missing the following minimum criteria: No adverse effect. Upon receipt of follow-up information on 15Apr2025, this case now contains all required information to be considered valid. This is a spontaneous report received from a Consumer or other non HCP, Program ID. A patient (age and gender not provided) received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Severe asthma" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1, single), for Covid-19 Immunization. The following information was reported: ASTHMA (non-serious), outcome "unknown", described as "a single person with severe asthma experienced worsening symptoms". Additional information: In a 2021 case study, a single person with severe asthma experienced worsening symptoms following the second dose of the Pfizer-BioNTech vaccine. However, researchers were not able to definitively establish a cause-and-effect relationship and were unable to draw conclusions based on a single case study. More research is necessary to determine whether any relationship exists. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.
Medical History/Concurrent Conditions: Asthma